Advertisement

Capella Healthcare to be sold to REIT in $900 million deal

By Beth Kutscher  |  July 27, 2015

Capella Healthcare, the privately held, Franklin, Tenn.-based chain, will be sold to a real estate investment trust in a $900 million deal. As more care moves to the outpatient setting, hospitals are hoping to find value in their bloated real estate portfolios.

Magellan Health's stock suffers on disappointing Q2 profit

By Bob Herman  |  July 27, 2015

Magellan Health reported Monday that second-quarter earnings fell far below Wall Street's expectations. Results at the managed-care and pharmacy benefits company have trended down in both quarters this year.

Israel's Teva buys Allergan's generic drug unit for $40.5B

By Associated Press  |  July 27, 2015

Israel's Teva Pharmaceutical Industries said Monday it is purchasing Dublin-based Allergan's generic pharmaceuticals business for $40.5 billion, in what analysts called the largest-ever acquisition by an Israeli company.

Covered California premiums creep up in 2016

By Virgil Dickson  |  July 27, 2015

Covered California enrollees will see premiums increase 4% in 2016, exchange officials said Monday. The increase is actually slightly less than the 4.2% jump consumers experienced between 2014 and 2015.

As patient volume rises, Ochsner plans growth strategy

By Beth Kutscher  |  July 27, 2015

An increase in patient volume at Ochsner Health System in New Orleans contributed to a higher operating margin in the first half of 2015 and the system is moving forward with new expansion projects.

CMS streamlines Medicaid waiver renewal process

By Virgil Dickson  |  July 27, 2015

The CMS has taken steps to ensure transparency and timely renewal of Medicaid demonstration waivers via new guidance. This comes weeks after facing congressional criticism and scrutiny over its oversight of the program. The agency also announced it's creating new ways for states to use 1115 waivers...

AstraZeneca sells rare cancer drug to Genzyme for $300 million

By Steven Ross Johnson  |  July 27, 2015

British pharmaceutical giant AstraZeneca plans to sell its thyroid cancer drug Caprelsa to Cambridge, Mass.-based Genzyme in a deal valued at $300 million. It's part of the company's strategy to move away from rare disease offerings and focus on key treatments.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.